Bevacizumab and neurodevelopmental outcomes of preterm infants with retinopathy of prematurity: should we still worry?

References

• Early Treatment for Retinopathy of Prematurity Cooperative G. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684–1694.
   PubMed Web of Science ®Google Scholar
• McCann ME, Schouten AN. Beyond survival; influences of blood pressure, cerebral perfusion and anesthesia on neurodevelopment. Paediatr Anaesth. 2014;24(1):68–73.
   PubMed Web of Science ®Google Scholar
• Geloneck MM, Chuang AZ, Clark WL, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132(11):1327–1333.
   PubMed Web of Science ®Google Scholar
• McLoone E, McLoone S, Lanigan B. Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of Goldmann perimetry at a mean age of 11 years. J Pediatr Ophthalmol Strabismus. 2007;44(3):170–173.
   PubMed Web of Science ®Google Scholar
• Mutlu FM, Sarici SU. Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol. 2013;6(2):228–236.
   PubMed Web of Science ®Google Scholar
• Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008;49(12):5177–5182.
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603–615.
   PubMed Web of Science ®Google Scholar
• Darlow BA, Ells AL, Gilbert CE, et al. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed. 2013;98(2):F170–F174.
   PubMed Web of Science ®Google Scholar
• Bas AY, Demirel N, Koc E, et al. Incidence, risk factors and severity of retinopathy of prematurity in Turkey (TR-ROP study): a prospective, multicentre study in 69 neonatal intensive care units. Br J Ophthalmol. 2018;102(12):1711–1716.
   PubMed Web of Science ®Google Scholar
• VanderVeen DK, Cataltepe SU. Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity. Semin Perinatol. 2019;43(6):375–380.
   PubMed Web of Science ®Google Scholar
• Morin J, Luu TM, Superstein R, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137(4):e20153218.
   PubMed Web of Science ®Google Scholar
• Raghuram K, Isaac M, Yang J, et al. Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser. J Perinatol. 2019;39(9):1300–1308.
   PubMed Web of Science ®Google Scholar
• Natarajan G, Shankaran S, Nolen TL, et al. Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment. Pediatrics. 2019;144(2):e20183537.
   PubMed Web of Science ®Google Scholar
• Lien R, Yu MH, Hsu KH, et al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLOS One. 2016;11(1):e0148019.
   PubMed Web of Science ®Google Scholar
• Inder TE, Perlman JM, Volpe JJ. Preterm intraventricular hemorrhage/posthemorrhagic hydrocephalus. In: Volpe JJ, editor. Volpe’s neurology of the newborn. 6th ed. Philadelphia: Elsevier; 2018. p. 637–698.
   Google Scholar
• Walsh MC, Yao Q, Gettner P, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics. 2004;114(5):1305–1311.
   PubMed Web of Science ®Google Scholar
• Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978;187(1):1–7.
   PubMed Web of Science ®Google Scholar
• Bayley N. Bayley scales of infant and toddler development. 3rd ed. Texas: The Psychological Corporation; 2006.
   Google Scholar
• Palisano R, Rosenbaum P, Walter S, et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39(4):214–223.
   PubMed Web of Science ®Google Scholar
• Celik P, Ayranci Sucakli I, Yakut HI. Which Bayley-III cut-off values should be used in different developmental levels? Turk J Med Sci. 2020;50(4):764–770.
   PubMed Web of Science ®Google Scholar
• Duncan AF, Bann C, Boatman C, et al. Do currently recommended Bayley-III cutoffs overestimate motor impairment in infants born <27 weeks gestation? J Perinatol. 2015;35(7):516–521.
   PubMed Web of Science ®Google Scholar
• Kong L, Bhatt AR, Demny AB, et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2015;56(2):956–961.
   PubMed Web of Science ®Google Scholar
• Hong YR, Kim YH, Kim SY, et al. Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection. Retina. 2015;35(9):1772–1777.
   PubMed Web of Science ®Google Scholar
• Rosenstein JM, Krum JM, Ruhrberg C. VEGF in the nervous system. Organogenesis. 2010;6(2):107–114.
   PubMed Web of Science ®Google Scholar
• Malik S, Vinukonda G, Vose LR, et al. Neurogenesis continues in the third trimester of pregnancy and is suppressed by premature birth. J Neurosci. 2013;33(2):411–423.
   PubMed Web of Science ®Google Scholar
• Chang YS, Chen YT, Lai TT, et al. Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment. PLOS One. 2019;14(10):e0223972.
   PubMed Web of Science ®Google Scholar
• Fan YY, Huang YS, Huang CY, et al. Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: a prospective case-control study. Ophthalmology. 2019;126(11):1567–1577.
   PubMed Web of Science ®Google Scholar
• Kennedy KA, Mintz-Hittner HA, BEAT-ROP Cooperative Group. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS. 2018;22(1):61–65.e1.
   PubMed Web of Science ®Google Scholar
• Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML, et al. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina. 2013;33(2):329–338.
   PubMed Web of Science ®Google Scholar
• Araz-Ersan B, Kir N, Tuncer S, et al. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. Curr Eye Res. 2015;40(6):585–591.
   PubMed Web of Science ®Google Scholar
• Su CH, Chen CJ, Ou-Yang MJ, et al. Premature infants with retinopathy received avastin tend to have lower plasma BDNF concentration and delayed mental development. Adv Biochem Biotechnol. 2018;3(4):170.
   Google Scholar
• Rodriguez SH, Peyton C, Lewis K, et al. Neurodevelopmental outcomes comparing bevacizumab to laser for type 1 ROP. Ophthalmic Surg Lasers Imaging Retina. 2019;50(6):337–343.
   PubMed Web of Science ®Google Scholar